Sarah Matthews
Acute Care · Greenville, SCNPI 1942618707
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,750 of the $28,227 with a category attached, or 77.1%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 82.7% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2023 at $11,363 and has fallen 92.9% since, to $812 in 2025. Among acute care clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $113.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23K
- Abbott$691
- Novartis$496
- Actelion Pharmaceuticals US, Inc.$446
- Cvrx, Inc.$367
- E.r. Squibb & Sons, L.L.C.$356
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$21,75077%
- Food & beverage$6,37823%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 90 | $23,351 |
| Abbott | 13 | $691 |
| Novartis | 34 | $496 |
| Actelion Pharmaceuticals US, Inc. | 7 | $446 |
| Cvrx, Inc. | 5 | $367 |
| E.r. Squibb & Sons, L.L.C. | 10 | $356 |
| United Therapeutics Corporation | 7 | $350 |
| Galderma Laboratories, L.p. | 5 | $295 |
| Impulse Dynamics (USA) Inc. | 6 | $278 |
| Boehringer Ingelheim | 11 | $191 |
| AstraZeneca | 9 | $189 |
| Boston Scientific | 2 | $187 |
| Abiomed | 5 | $157 |
| Kestra Medical Technology Services, Inc. | 6 | $118 |
| Bridgebio Pharma, Inc. | 3 | $108 |
| Amgen | 5 | $81 |
| Pfizer | 5 | $67 |
| Johnson & Johnson | 3 | $62 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $60 |
| Alnylam Pharmaceuticals Inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $44 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Merck | 2 | $37 |
| KARL Storz Endoscopy-america | 1 | $35 |
| Olympus America Inc. | 1 | $22 |
| Revance Therapeutics, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$21,980
- CARDIOMEMS$538
- Barostim Neo System$295
- OPTIMIZER$267
- CAMZYOS$257
- UPTRAVI$222
- OPSUMIT$222
- GENERAL - THERAPIES$168
- TYVASO$124
- DYSPORT$109
How this compares
$28,227 in reported general payments places this provider in the 95th percentile of 339 acute care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 49 | $1,055,871 |
| EntrestoSacubitril/Valsartan | 182 | $181,573 |
| JardianceEmpagliflozin | 111 | $114,363 |
| EliquisApixaban | 111 | $96,845 |
| FarxigaDapagliflozin Propanediol | 78 | $72,001 |
| DapagliflozinDapagliflozin Propanediol | 17 | $8,744 |
| Sildenafil Citrate | 11 | $3,500 |
| Torsemide | 149 | $3,097 |
| Metoprolol Succinate | 143 | $2,446 |
| Spironolactone | 223 | $1,573 |
| Tadalafil | 13 | $1,540 |
| Eplerenone | 24 | $1,328 |
| Amiodarone Hcl | 13 | $736 |
| Bumetanide | 16 | $668 |
| Atorvastatin Calcium | 54 | $569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $67 | $1,152,716160 claims |
| NovartisEntresto | $496 | $181,573182 claims |
| Boehringer IngelheimJardiance | $191 | $114,363111 claims |
| AstraZenecaFarxiga | $189 | $72,00178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 acute care providers in South Carolina.
Other acute care in Greenville
- Heather BowersGreenville$94K
- Susan FunkGreenville$11K
- Jeffrey CobbGreenville$8K
- Jamez FletcherGreenville$7K
- Serena KocourekGreenville$7K
- Taylor NewtonGreenville$6K
- Cheryl MartinezGreenville$6K
- Stephanie RodriguezGreenville$6K
- Lucretia MyersGreenville$5K
- Jessica SentellGreenville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.